How Did Novartis Perform in 3Q17?
Novartis revenue trends
In 3Q17, Novartis (NVS) reported revenues of ~$12.4 billion, which was ~2% higher YoY (year-over-year) and 1% higher QoQ (quarter-over-quarter).
In 3Q17, Novartis reported operating income of $2.36 billion, compared with $2.27 billion in 3Q16. In 3Q17, Novartis reported net income of ~$2.1 billion, compared with $1.9 billion in 3Q16. In 3Q17, the company reported basic EPS (earnings per share) of $0.89, compared with $0.81 in 3Q16. In 3Q17, Novartis reported free cash flow of $3.06 billion, compared with $2.59 billion in 3Q16.
Interested in NVS? Don't miss the next report.
Receive e-mail alerts for new research on NVS
From January 2017 to September 2017, Novartis generated revenues of ~$36.2 billion. Novartis Cosentyx, Entresto, Promacta, and Tafinlar-Mekinist primarily attributed to this revenue growth during the first nine months of 2017.
In October 2017, Novartis (NVS) submitted a supplemental Biologics License Application (or sBLA) to the FDA (US Food and Drug Administration) for Kymriah for the treatment of adult individuals with relapsed or refractory DLBCL (diffuse large B-cell lymphoma) who are not eligible for autologous stem cell transplant (or ASCT).
In April 2017, the FDA established a Breakthrough Therapy designation for Kymriah for the treatment of individuals with DLBCL. Novartis’s sBLA submission to the FDA was based on the phase-2 Juliet trial, which evaluated the safety and efficacy of Kymriah exclusively for DLBCL.
Previously, Kymriah had received FDA approval for the treatment of individuals under 25 years of age with B-cell precursor acute lymphoblastic leukemia (or ALL) that has relapsed at least twice.
By comparison, Pfizer (PFE), Merck (MRK), Bristol-Myers Squibb (BMY), and Roche reported revenues of ~$13.2 billion, ~$10.3 billion, ~$5.3 billion, and ~26.3 billion Swiss francs, respectively. The Vanguard FTSE Developed Markets ETF (VEA) has ~0.78% of its total portfolio holdings in NVS.